SCHEMBL20455697

SCHEMBL20455697

CCOC(=O)CC(C)C(=O)c1cc(F)c(F)c(F)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.42
CES1 P23141 2/20 0.42
ALDH1A1 P00352 4/20 0.35
TSHR P16473 3/20 0.35
NLRP3 Q96P20 1/20 0.35
CYP3A4 P08684 1/20 0.34
ALOX15 P16050 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
F10 P00742 4/20 0.34
F2 P00734 3/20 0.34
PRSS1 P07477 1/20 0.34
KDM4E B2RXH2 2/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA7 P43166 1/20 0.33
CA9 Q16790 1/20 0.33
CA14 Q9ULX7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26673197 0.86 SLC6A3 (0.43) CES2CES1ALDH1A1TSHRCYP3A4
SCHEMBL16150533 0.85 CHRNA1 (0.47) CES2CES1ALDH1A1TSHRF10
SCHEMBL20455676 0.79 ALDH1A1 (0.43) ALDH1A1TSHRCYP3A4ALOX15KDM4E
SCHEMBL10510642 0.76 CES2 (0.46) CES2CES1ALDH1A1TSHRALOX15
SCHEMBL11732434 0.76 KMT2A (0.53) ALDH1A1TSHRF10F2MEN1
SCHEMBL1376478 0.75 CA12 (0.54) ALDH1A1TSHRTDP1KMT2ACA12
SCHEMBL6204940 0.75 NPC1 (0.47) CES2CES1ALDH1A1TSHRNLRP3
SCHEMBL9806430 0.74 LMNA (0.56) ALDH1A1TSHRCYP3A4F10F2
SCHEMBL11730496 0.74 SMN1; SMN2 (0.48) ALDH1A1TSHRCYP3A4TDP1MEN1
SCHEMBL29654058 0.74 NPC1 (0.57) ALDH1A1TSHRALOX15MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110831599-B Compounds, compositions and methods for cancer treatment 布罗德研究所股份有限公司 2023-03-28 CN disclosed
US-11142522-B2 Compounds, compositions and methods for cancer treatment THE BROAD INSTITUTE, INC. (US) 2021-10-12 US disclosed
US-11142522-B2 Compounds, compositions and methods for cancer treatment THE BROAD INSTITUTE, INC. (US) 2021-10-12 US disclosed
US-20200062741-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CANCER TREATMENT THE BROAD INSTITUTE, INC. (US) 2020-02-27 US disclosed
US-20200062741-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CANCER TREATMENT THE BROAD INSTITUTE, INC. (US) 2020-02-27 US disclosed
CN-110831599-A Compounds, compositions and methods for cancer treatment 布罗德研究所股份有限公司 2020-02-21 CN disclosed
WO-2018141835-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CANCER TREATMENT THE BROAD INSTITUTE, INC. (US) 2018-08-09 WO disclosed
WO-2018141835-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CANCER TREATMENT THE BROAD INSTITUTE, INC. (US) 2018-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200062741-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CANCER TREATMENT CREB1, PDE2A, PDE4A CES2 828/4885CES1 1959/4885ALDH1A1 1509/4885
US-11142522-B2 Compounds, compositions and methods for cancer treatment CREB1, PDE2A, PDE4A CES2 828/4885CES1 1959/4885ALDH1A1 1509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.